This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Donald W. Kufe, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00003761
First received: November 1, 1999
Last updated: February 13, 2017
Last verified: February 2017
  Purpose
This protocol is designed to evaluate the side effects of rV-DF3/MUC1 and to determine the safest dose which should be used in the treatment of breast cancer.

Condition Intervention Phase
Breast Cancer Biological: rV-DF3/MUC1 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase I Trial of Recombinant Vaccinia Virus That Expresses DF3/MUC1 in Patients With Metastatic Adenocarcinoma of the Breast

Resource links provided by NLM:


Further study details as provided by Donald W. Kufe, Dana-Farber Cancer Institute:

Enrollment: 20
Actual Study Start Date: March 3, 1999
Study Completion Date: October 19, 2001
Primary Completion Date: April 20, 2001 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: rV-DF3/MUC1
  • rV-DF3/MUC1 vaccinations will be administered 4 week intervals for a total of 3 doses.
  • Participants will be followed weekly until 28 days after the final dose (day 85) then month for 6 months
Biological: rV-DF3/MUC1

- The starting dose for this Phase I study of rV-DF3/MUC1 will be 4.76 x 106 PFU.

-- Dose escalation will proceed with cohorts of at least 6 patients as follows: Per vaccination

  • Level 1 4.76 x 106 PFU
  • Level 2 4.76 x 107 PFU
  • Level 3 4.76 x 108 PFU

Detailed Description:

OBJECTIVES: I. Determine the toxicity associated with repeated vaccination with recombinant vaccinia DF3/MUC1 vaccine (rV-DF3/MUC1) in patients with metastatic breast cancer. II. Determine the maximum tolerated dose of rV-DF3/MUC1, based on cellular and humoral immunity, in these patients. III. Determine whether vaccination with rV-DF3/MUC1 is associated with antitumor activity in these patients.

OUTLINE: This is an open label, dose escalation study. Patients receive recombinant vaccinia DF3/MUC1 vaccine (rV-DF3/MUC1) intradermally. Treatment repeats every month for 3 courses in the absence of disease progression or unacceptable toxicity. Cohorts of at least 6 patients receive escalating doses of rV-DF3/MUC1 until the maximum tolerated dose (MTD) or the highest dose level to be tested is reached. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity. Patients are followed monthly for 6 months.

PROJECTED ACCRUAL: A total of 16-28 patients will be accrued for this study within 1-2 years.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • Inclusion Criteria
  • Patients with a histologically confirmed diagnosis of metastatic adenocarcinoma of the breast. Patients may have measurable disease, but it is not required. Patients may have received any number of prior therapies for metastatic disease. Untreated patients are also eligible.
  • Age ≥ 18 years
  • Patients must have an ECOG = Performance Status of 0-1
  • Patients must have a WBC > 2000/mm 3 and a platelet count > 100,000/mm3.
  • Patients must have adequate renal function documented by a serum creatinine < 2.0 mg/d1.
  • Patients must have adequate liver function demonstrated by a serum bilirubin < 2.0 mg/di, and a SGPT < 4 times the upper limit of normal.
  • ≥3 weeks since chemotherapy (> 6 weeks for nitosoureas or mitomycin C), hormonal therapy or radiation therapy
  • Immunologic testing must be at least normal as defined by at least normal delayed type hypersensitivity, at least normal CD4: CD8 ratio (>1), at least normal lymphocyte proliferation testing (to Con A), and at least normal immunoglobulin levels
  • Patients must not have evidence of altered immune responsiveness or autoimmune syndromes (scleroderma,systemic lupus erythematosus, etc.). Patients must be HIV negative. This treatment may be associated with increased adverse effects for individuals with immune deficiencies, and HIV-associated symptoms preclude accurate assessment of toxicity.
  • Patients must not have undergone splenectomy.
  • Patients with active cases or history of extensive skin disorders (such as extensive psoriasis, burns, impetigo, disseminated zoster) are ineligible.
  • Patients must not have any other serious medical condition which in the opinion of the investigator is incompatible with the protocol. Patients with active infections requiring antibiotics are not eligible until the infection has cleared and the antibiotics have been stopped for at least 3 days.
  • Patients must be able to avoid close contact with children < 3 years of age, pregnant women, individuals with eczema or skin conditions and immune suppressed individuals during a period of two weeks after each vaccination.
  • Patients must have had prior vaccinia (small pox) exposure.
  • Tumor tissue positive for staining with MAbs DF3 and/or DF3-P or elevated serum CA15-3. Note: This can be done on stored slides.
  • Patients must not have a history of seizures, encephalitis or multiple sclerosis.
  • Patients must not be allergic to eggs.
  • Patients must not be pregnant or breast-feeding due to a possible increased risk with exposure to vaccinia virus of both mother and newborn as well as unknown risks to the fetus.
  • Signed informed consent.
  • Exclusion Criteria
  • Patients must not have evidence of altered immune responsiveness or autoimmune syndromes (scleroderma, systemic lupus erythematosus, etc.). Patients must be HIV negative This treatment may be associated with increased adverse effects for individuals with immune deficiencies, and HIV-associated symptoms preclude accurate assessment of toxicity.
  • Patients must not have undergone splenectomy
  • Patients with active cases or history of extensive skin disorders (such as extensive psoriasis, burns, impetigo, disseminated zoster) are ineligible.
  • Patients must not have any other serious medical condition which in the opinion of the investigator is incompatible with the protocol. Patients with active infections requiring antibiotics are not eligible until the infection has cleared and the antibiotics have been stopped for at least 3 days.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00003761

Locations
United States, Massachusetts
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States, 02114
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Boston Medical Center
Boston, Massachusetts, United States, 02118
Sponsors and Collaborators
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Investigators
Study Chair: Donald W. Kufe, MD Dana-Farber Cancer Institute
  More Information

Responsible Party: Donald W. Kufe, Kufe, Donald William,M.D., Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT00003761     History of Changes
Other Study ID Numbers: 97-050
U01CA062490 ( US NIH Grant/Contract Award Number )
P30CA006516 ( US NIH Grant/Contract Award Number )
NCI-T98-0057 ( Other Identifier: Protocol relative to DFPCC #97-050 )
Study First Received: November 1, 1999
Last Updated: February 13, 2017
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Donald W. Kufe, Dana-Farber Cancer Institute:
stage IV breast cancer
recurrent breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on June 23, 2017